QualityDipStocks / Health Care · Pharmaceuticals
Jazz Pharmaceuticals JAZZ
Outside our quality screen, so we don’t track its dips. It’s 17% below its 52-week high.
Outside our quality screen, trading well below our fair value estimate.
- Fair value est.
- $412.73+91%
- Market Value
- forming
- Off 52-wk high
- −17%
- Risk vs market
- Lowbeta 0.47
5 bullish · 5 bearish See why
Key levels
Every level vs today’s $215.98
- 52-wk lowlowest close, 1 year$131.16−39.3%
- PriceFri Oct 30 close$215.98you are here
- 52-wk highhighest close, 1 year$261.62+21.1%
- Fair value est.base case$412.73+91.1%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 5.3% ±2 points. Bear = 10.5% and 3.3%; bull = 8.5% and 7.3% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is below even the bear case.
What the price implies To be worth today’s price, JAZZ’s free cash flow would need to shrink about 6% a year for five years; our estimate uses 5%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much JAZZ moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves much less than the market, but its own price swings are 2.9× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.47
- Volatility
- 38% vs 13% SPY
- Correlation SPY
- 0.16
- Correlation QQQ
- 0.13
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ValuationOur DCF fair value estimate is $412.73, 91% above the price.
ValuationFree-cash-flow yield of 10.6% (price / FCF 9.4×): $1.6B of free cash in the last 12 months.
ValuationP/E of 15.9× vs a 29.2× median for the 86 Health Care companies we cover.
ProfitabilityReturn on equity of 22% over the last 12 months.
GrowthSales grew 13% to $4.6B over the last 12 months vs the 12 months before (SEC filings).
Top bearish points 5 of 5
ProfitabilityOperating margin narrowed to −10.1% in FY2025 from 15.1% in FY2023 (SEC filings).
Cash returnsShare count up 13.4% in a year: existing holders are being diluted.
ProfitabilityReturn on equity fell 19 points in two fiscal years, to -8% in FY2025.
Balance sheetDebt / equity of 0.9×, above the 0.7× median for the 67 Health Care companies we cover.
RiskReports earnings Nov 2 (consensus EPS ($5.18)): results can move the price sharply and reset Market Value.
Who’s talking about it
Notable investors, executives, analysts and public figures on Jazz Pharmaceuticals in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
All fundamentals
P/E 15.9 · FCF yield 10.6% · ROE 22%
Valuation
- P/E
- 15.9×Health Care median 29.2×
- Price / FCF
- 9.4×
- FCF yield
- 10.6%
- EV / EBITDA
- 11.0×
- Price / sales
- 3.26×
- Price / book
- 3.12×
- Market cap
- $15.0Bprice × diluted shares
- Enterprise value
- $17.7B
Growth
- Revenue, 12 months
- $4.6B
- Sales growth, 12 months
- +12.6%vs the 12 months before
- Sales growth, 3 yrs
- +5.3%/yrfrom FY2022
- Diluted EPS, 12 months
- $14.61
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- $941M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- 19.5%
- Net margin
- 20.4%
- FCF margin
- 34.6%
- Return on equity
- 22%
- Return on invested capital
- 12%
Balance sheet
- Cash & short-term inv.
- $1.6B
- Total debt
- $4.4B
- Net cash
- −$2.7B
- Debt / equity
- 0.91×
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- $1.6B
- FCF growth, 12 months
- +26%
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $23,0000.0% of market cap
- Share count, 1 year
- +13.4%diluted shares vs a year ago
- Stock-based comp
- $307M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Jazz Pharmaceuticals’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $412.73 · FCF value $571.95
Assumes 5.3% growth for 5 years (revenue grew 5.3% a year FY22–FY25), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $22.93 a share (trailing 12 months to Jun 30, 2026), from the 10-Q filed Aug 3, 2026. Net debt $2.7B, not deducted.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 46 · 5 days +0.9%
The business
FCF $1.4B · Sales +16%
- Free cash flow, 12 months$1.4B
- Free-cash-flow yield10.6%
- Free-cash-flow margin31%
- Gross margin91%
- Operating margin27%
- Return on invested capital14%
- Return on equity22%
- Sales growth (latest quarter vs year-ago quarter)+16%
- Net debt / EBITDA1.1×
Next report
Nov 2
- DateMon Nov 2, after the close
- Consensus EPS($5.18)
- Year-ago EPS$6.99
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
JAZZ is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.